Drug Trial Radar · NCT00150566
Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood
Last checked: Nov 20, 2026Latest source record: Jun 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
460
Actual
Start
Feb 9, 2004
Primary completion
Oct 8, 2005
Study completion Oct 8, 2005
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 8, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test how well higher doses of lanthanum carbonate reduce the pre-dialysis level of serum phosphorus in subjects undergoing dialysis due to end stage renal disease.
Conditions
- Kidney Failure, Chronic
Interventions
Lanthanum carbonateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pre-dialysis serum phosphate levels after 4 and 8 weeks of treatmentTime frame: 4 & 8 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.